NeoGenomics (NEO) Receives a Buy from Raymond James

Raymond James analyst Andrew Cooper maintained a Buy rating on NeoGenomics (NEOResearch Report) today and set a price target of $12.00. The company’s shares closed yesterday at $10.08.

According to TipRanks, Cooper is an analyst with an average return of -21.5% and a 27.08% success rate. Cooper covers the Healthcare sector, focusing on stocks such as LumiraDx, Exact Sciences, and Haemonetics.

In addition to Raymond James, NeoGenomics also received a Buy from Goldman Sachs’s Matthew Sykes in a report issued on November 9. However, on the same day, Morgan Stanley maintained a Hold rating on NeoGenomics (NASDAQ: NEO).

See Insiders’ Hot Stocks on TipRanks >>

Based on NeoGenomics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $125.07 million and a GAAP net loss of $35.3 million. In comparison, last year the company earned a revenue of $121.72 million and had a net profit of $75.87 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients’ oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Read More on NEO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More